NCT06708572View on ClinicalTrials.gov

Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Granulocyte Colony-stimulating FactorBiliary Atresia
Interventions
DRUG

Granulocyte Colony-Stimulating Factor

20 patients will receive subcutaneous GCSF at a daily dose of 10ug/kg for 3 consecutive days. It is administered within 3-4 days after the Kasai procedure.

Trial Locations (1)

32511

RECRUITING

National Liver Institute, Cairo

All Listed Sponsors
lead

National Liver Institute, Egypt

OTHER